NeuroLab

NeuroLab sits at the intersection of mental-health technology, EEG-based assessment, medical devices, and brain-computer interfaces. Its described software concept combines brain-data analysis with a mobile interface for mental wellness support, while its hardware-oriented work addresses neural recording and human-computer interaction. The stated technical scope—128–512-channel electrode arrays, analog signal conditioning, and neural decoding—suggests an ambition to address complex clinical and research applications rather than only consumer wellness. The profile also emphasizes fail-safes, continuous monitoring, open data formats, transparent methods, privacy, consent, and neuroethics as design considerations. Its differentiation can therefore only be described in terms of its stated combination of EEG-based mental-health tools and clinical-grade neural-interface development, alongside an explicit safety and ethics focus. The company is private, was founded in 2024, and has an indicated employee range of 1–10.

NeuroLab was founded on Jan 1, 2024, is privately held, and has an indicated employee range of 1–10. Its stated scope spans two related but distinct areas: AI-supported EEG mental-health assessment delivered through a mobile experience, and neural interfaces for clinical use and human-computer interaction. The described technical work—from 128–512-channel recording architectures and analog signal conditioning to decoding models and cursor-control paradigms—suggests a substantial engineering and validation agenda. There is also no disclosed funding total or valuation with which to assess the resources available for development. Accordingly, the company’s trajectory cannot yet be characterized as accelerating or stalled on the basis of the current profile. The clearest indicators to watch would be evidence of clinical validation, deployment of the mobile mental-health product, regulatory progress for devices, and partnerships that connect its research and engineering work to care settings.